The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma

被引:8
作者
Zhou, Yongying [1 ]
Wang, Xiao [2 ]
Zhang, Weibing [1 ]
Liu, Huiyong [3 ]
Liu, Daoquan [1 ]
Chen, Ping [1 ]
Xu, Deqiang [1 ]
Liu, Jianmin [1 ]
Li, Yan [1 ]
Zeng, Guang [1 ]
Li, Mingzhou [1 ]
Wu, Zhonghua [1 ]
Zhang, Yingao [1 ]
Wang, Xinghuan [1 ]
DiSanto, Michael E. [4 ]
Zhang, Xinhua [1 ]
机构
[1] Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China
[2] Wuhan Univ, Dept Rehabil Med, Renmin Hosp, Wuhan, Peoples R China
[3] Huanggang Cent Hosp, Dept Urol, Huanggang, Peoples R China
[4] Rowan Univ, Dept Surg & Biomed Sci, Cooper Med Sch, Camden, NJ USA
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
中国国家自然科学基金;
关键词
prognosis; biomarker; clear cell renal cell carcinoma; HCST; immune-related gene; DENDRITIC CELLS; CANCER; IMMUNOTHERAPY; THERAPIES; SURVIVAL;
D O I
10.3389/fonc.2021.630706
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney tumor worldwide. Analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases showed that the immune-related gene (IRG) hematopoietic cell signal transducer (HCST) could provide guidance for the diagnosis, prognosis, and treatment of ccRCC. The RNA-seq data of ccRCC tissues were extracted from two databases: TCGA (https://www.cancer.gov/about-nci/organization/ ccg/research/structural-genomics/ tcga) and GEO (https://www.ncbi.nlm.nih.gov/ geo/). Corresponding clinical information was downloaded from TCGA. Immune-related gene data were extracted from the IMMPORT website (https://www.immport.org/). Differential analysis with R software (https://www.r-project.org/) was used to obtain a prognosis model of ccRCC IRGs. The differences were combined with the clinical data to assess the usefulness of the HCST as a prognostic biomarker. Based on data obtained from the Oncomine (https://www.oncomine.org/), Human Protein Atlas (https://www.proteinatlas. org/), and PubMed (https://pubmed.ncbi.nlm.nih.gov/) databases, the expression levels of the HCST in ccRCC, clinical-pathological indicators of relevance, and influence on prognosis were analyzed. Regulation of the HCST gene in ccRCC was assessed by gene set enrichment analysis (GSEA). In TCGA/GEO databases, the high HCST expression in tumor tissues was significantly correlated to the TMN stage, tumor grade, invasion depth, and lymphatic metastasis (p < 0.05). The overall survival (OS) of patients with high HCST gene expression was significantly lower than that of patients with low HCST gene expression (p < 0.001). Multivariate Cox regression analysis suggested that the HCST expression level [hazard ratio (HR) = 1.630, 95% confidence interval (CI) = 1.042-2.552], tumor cell grade (HR = 1.829, 95% CI = 1.115-3.001), and distant metastasis (HR = 2.634, 95%, CI = 1.562-4.442) were independent risk factors affecting the OS of ccRCC patients (all, p < 0.05). The GSEA study showed that there was significant enrichment in cell adhesion, tumorigenesis, and immune and inflammatory responses in HCST high expression samples. Hematopoietic cell signal transducer expression was closely associated with the levels of infiltrating immune cells around ccRCC tissues, especially dendritic cells (DCs). In conclusion, the present study suggested that the HCST was interrelated to the clinicopathology and poor prognosis of ccRCC. High HCST expression was also closely correlated with the levels of tumor-infiltrating immune cells, especially DCs.
引用
收藏
页数:15
相关论文
共 35 条
  • [1] Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
    Atkins, Michael B.
    Tannir, Nizar M.
    [J]. CANCER TREATMENT REVIEWS, 2018, 70 : 127 - 137
  • [2] Treatment of renal cell carcinoma: Current status and future directions
    Barata, Pedro C.
    Rini, Brian I.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) : 507 - 524
  • [3] A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
    Barry, Kevin C.
    Hsu, Joy
    Broz, Miranda L.
    Cueto, Francisco J.
    Binnewies, Mikhail
    Combes, Alexis J.
    Nelson, Amanda E.
    Loo, Kimberly
    Kumar, Raj
    Rosenblum, Michael D.
    Alvarado, Michael D.
    Wolf, Denise M.
    Bogunovic, Dusan
    Bhardwaj, Nina
    Daud, Adil, I
    Ha, Patrick K.
    Ryan, William R.
    Pollack, Joshua L.
    Samad, Bushra
    Asthana, Saurabh
    Chan, Vincent
    Krummel, Matthew F.
    [J]. NATURE MEDICINE, 2018, 24 (08) : 1178 - 1191
  • [4] Novel immunotherapies in lymphoid malignancies
    Batlevi, Connie Lee
    Matsuki, Eri
    Brentjens, Renier J.
    Younes, Anas
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (01) : 25 - 40
  • [5] DC Respond to Cognate T Cell Interaction in the Antigen-Challenged Lymph Node
    Curato, Caterina
    Bernshtein, Biana
    Zupancic, Eva
    Dufner, Almut
    Jaitin, Diego
    Giladi, Amir
    David, Eyal
    Chappell-Maor, Louise
    Leshkowitz, Dena
    Knobeloch, Klaus-Peter
    Amit, Ido
    Florindo, Helena F.
    Jung, Steffen
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [6] Cancer Neoantigens and Applications for Immunotherapy
    Desrichard, Alexis
    Snyder, Alexandra
    Chan, Timothy A.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (04) : 807 - 812
  • [7] Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
    Fu, Chunmei
    Jiang, Aimin
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [8] Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
    Galon, Jerome
    Bruni, Daniela
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (03) : 197 - 218
  • [9] Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma
    Giraldo, Nicolas A.
    Becht, Etienne
    Vano, Yann
    Petitprez, Florent
    Lacroix, Laetitia
    Validire, Pierre
    Sanchez-Salas, Rafael
    Ingels, Alexandre
    Oudard, Stephane
    Moatti, Audrey
    Buttard, Benedicte
    Bourass, Sarah
    Germain, Claire
    Cathelineau, Xavier
    Fridman, Wolf H.
    Sautes-Fridman, Catherine
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4416 - 4428
  • [10] Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial
    Hakimi, A. Ari
    Voss, Martin H.
    Kuo, Fengshen
    Sanchez, Alejandro
    Liu, Ming
    Nixon, Briana G.
    Vuong, Lynda
    Ostrovnaya, Irina
    Chen, Ying-Bei
    Reuter, Victor
    Riaz, Nadeem
    Cheng, Yuan
    Patel, Parul
    Marker, Mahtab
    Reising, Albert
    Li, Ming O.
    Chan, Timothy A.
    Motzer, Robert J.
    [J]. CANCER DISCOVERY, 2019, 9 (04) : 510 - 525